Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors

The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and... RESEARCH ARTICLE The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors Ankur R. Sangoi, MD,* Bijayee Shrestha, MD, PhD,* George Yang, MD,w Ourhay Mego, BS,w and Andrew H. Beck, MD, PhDz relations of GCDFP15 [Pearson’s correlation = 0.57 (0.33-0.74)] Abstract: Traditional markers mammaglobin and GCDFP15 and mammaglobin [Pearson’s correlation = 0.50 (0.24-0.70)] show good specificity but lack sensitivity and can be difficult to (both P < 0.05). In conclusion, the novel marker GATA3 stains interpret in small tissue samples. We undertook a comparative a significantly higher proportion of both primary and metastatic study of the novel nuclear marker GATA3 (expression typically breast carcinomas than GCDFP15 or mammaglobin with restricted to breast and urothelial carcinomas) and GCDFP15 stronger and more diffuse staining, helpful in cases with small and mammaglobin. We first compared quantitative mRNA ex- tissue samples. The matched primary/metastatic expression of pression levels of these 3 markers across a diverse set of over GATA3 is also more consistent. We propose that GATA3 be 6000 tumors and 500 normal samples from The Cancer Genome included among a panel of confirmatory http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors

Beck, Andrew H.
Applied Immunohistochemistry & Molecular Morphology , Volume Publish Ahead of Print – Apr 1, 2015
Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/the-novel-marker-gata3-is-significantly-more-sensitive-than-A7KrOQf0jW

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000186
pmid
25906123
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors Ankur R. Sangoi, MD,* Bijayee Shrestha, MD, PhD,* George Yang, MD,w Ourhay Mego, BS,w and Andrew H. Beck, MD, PhDz relations of GCDFP15 [Pearson’s correlation = 0.57 (0.33-0.74)] Abstract: Traditional markers mammaglobin and GCDFP15 and mammaglobin [Pearson’s correlation = 0.50 (0.24-0.70)] show good specificity but lack sensitivity and can be difficult to (both P < 0.05). In conclusion, the novel marker GATA3 stains interpret in small tissue samples. We undertook a comparative a significantly higher proportion of both primary and metastatic study of the novel nuclear marker GATA3 (expression typically breast carcinomas than GCDFP15 or mammaglobin with restricted to breast and urothelial carcinomas) and GCDFP15 stronger and more diffuse staining, helpful in cases with small and mammaglobin. We first compared quantitative mRNA ex- tissue samples. The matched primary/metastatic expression of pression levels of these 3 markers across a diverse set of over GATA3 is also more consistent. We propose that GATA3 be 6000 tumors and 500 normal samples from The Cancer Genome included among a panel of confirmatory

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Apr 1, 2015

There are no references for this article.